This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2024 Nov;12(11):e20.

doi: 10.1016/S2213-8587(24)00288-2. Epub 2024 Sep 13.

Correction to Lancet Diabetes Endocrinol 2024; 12: 39-50

No authors listed

PMID: 39284330
DOI: 10.1016/S2213-8587(24)00288-2

Free article

Published Erratum

Correction to Lancet Diabetes Endocrinol 2024; 12: 39-50

No authors listed. Lancet Diabetes Endocrinol. 2024 Nov.

Free article

. 2024 Nov;12(11):e20.

doi: 10.1016/S2213-8587(24)00288-2. Epub 2024 Sep 13.

PMID: 39284330
DOI: 10.1016/S2213-8587(24)00288-2

No abstract available

PubMed Disclaimer

Erratum for

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science